Amilca-Seba Katyana, Sabbah Michèle, Larsen Annette K, Denis Jérôme A
Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), 75012 Paris, France.
Institut National de la Santé et de la Recherche Médicale (INSERM) U938, 75012 Paris, France.
Cancers (Basel). 2021 Jul 28;13(15):3793. doi: 10.3390/cancers13153793.
A high expression of the phosphoprotein osteopontin (OPN) has been associated with cancer progression in several tumor types, including breast cancer, hepatocarcinoma, ovarian cancer, and colorectal cancer (CRC). Interestingly, OPN is overexpressed in CRC and is associated with a poor prognosis linked to invasion and metastasis. Here, we review the regulation and functions of OPN with an emphasis on CRC. We examine how epigenetic and genetic regulators interact with the key signaling pathways involved in this disease. Then, we describe the role of OPN in cancer progression, including proliferation, survival, migration, invasion, and angiogenesis. Furthermore, we outline the interest of using OPN as a clinical biomarker, and discuss if and how osteopontin can be implemented as a routine assay in clinical laboratories for monitoring CRC patients. Finally, we discuss the use of OPN an attractive, but challenging, therapeutic target.
磷蛋白骨桥蛋白（OPN）的高表达与包括乳腺癌、肝癌、卵巢癌和结直肠癌（CRC）在内的多种肿瘤类型的癌症进展相关。有趣的是，OPN在结直肠癌中过度表达，并与侵袭和转移相关的不良预后有关。在这里，我们综述OPN的调控和功能，重点是结直肠癌。我们研究表观遗传和遗传调节因子如何与该疾病涉及的关键信号通路相互作用。然后，我们描述OPN在癌症进展中的作用，包括增殖、存活、迁移、侵袭和血管生成。此外，我们概述了将OPN用作临床生物标志物的意义，并讨论骨桥蛋白是否以及如何能够作为临床实验室监测结直肠癌患者的常规检测方法来实施。最后，我们讨论将OPN作为一个有吸引力但具有挑战性的治疗靶点的应用。
